Measured Wealth Private Client Group LLC Takes $677,000 Position in Medpace Holdings Inc (MEDP)

Measured Wealth Private Client Group LLC purchased a new stake in shares of Medpace Holdings Inc (NASDAQ:MEDP) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,480 shares of the company’s stock, valued at approximately $677,000.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. LS Investment Advisors LLC acquired a new position in shares of Medpace during the fourth quarter valued at $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new position in shares of Medpace during the fourth quarter valued at $87,000. State of Alaska Department of Revenue acquired a new position in shares of Medpace during the fourth quarter valued at $92,000. NumerixS Investment Technologies Inc acquired a new position in shares of Medpace during the fourth quarter valued at $119,000. Finally, We Are One Seven LLC acquired a new position in Medpace in the fourth quarter valued at about $130,000. 83.50% of the stock is currently owned by institutional investors and hedge funds.

In other Medpace news, CFO Jesse J. Geiger sold 25,037 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $60.00, for a total value of $1,502,220.00. Following the completion of the sale, the chief financial officer now directly owns 25,037 shares in the company, valued at $1,502,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jesse J. Geiger sold 12,000 shares of the stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $58.20, for a total value of $698,400.00. Following the completion of the sale, the chief financial officer now owns 25,037 shares of the company’s stock, valued at $1,457,153.40. The disclosure for this sale can be found here. Insiders sold 44,983 shares of company stock valued at $2,661,091 over the last 90 days. Corporate insiders own 24.20% of the company’s stock.

Several research firms have weighed in on MEDP. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 8th. TheStreet raised Medpace from a “c” rating to a “b-” rating in a research note on Wednesday, April 10th. Wolfe Research began coverage on Medpace in a research note on Tuesday, April 2nd. They issued an “outperform” rating on the stock. Robert W. Baird increased their target price on Medpace from $57.00 to $62.00 and gave the company a “neutral” rating in a research note on Tuesday, April 30th. Finally, ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $59.25.

NASDAQ:MEDP traded up $1.21 during mid-day trading on Thursday, hitting $56.45. The company had a trading volume of 2,202 shares, compared to its average volume of 621,274. Medpace Holdings Inc has a fifty-two week low of $40.65 and a fifty-two week high of $71.66. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 21.81, a PEG ratio of 1.63 and a beta of 1.51. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.09.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Medpace had a return on equity of 17.16% and a net margin of 10.49%. The company had revenue of $200.70 million during the quarter, compared to the consensus estimate of $190.16 million. During the same period in the prior year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 23.1% compared to the same quarter last year. Sell-side analysts predict that Medpace Holdings Inc will post 2.63 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Measured Wealth Private Client Group LLC Takes $677,000 Position in Medpace Holdings Inc (MEDP)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2019/05/16/measured-wealth-private-client-group-llc-takes-677000-position-in-medpace-holdings-inc-medp.html.

Medpace Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: What is the quiet period?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit